Cargando…

Therapeutic Use of Immunoglobulins

Detalles Bibliográficos
Autores principales:	Stiehm, E. Richard, Orange, Jordan S., Ballow, Mark, Lehman, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112008/ https://www.ncbi.nlm.nih.gov/pubmed/21056739 http://dx.doi.org/10.1016/j.yapd.2010.08.005

Ejemplares similares

Corrigendum: Specific Antibody Deficiency: Controversies in Diagnosis and Management
por: Perez, Elena, et al.
Publicado: (2018)

Specific Antibody Deficiency: Controversies in Diagnosis and Management
por: Perez, Elena, et al.
Publicado: (2017)

Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses
por: Orange, Jordan S., et al.
Publicado: (2015)

Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy
por: Gonzalez, Juan Marcos, et al.
Publicado: (2022)

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2017)

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2018)

Prioritization of Evidence-Based Indications for Intravenous Immunoglobulin
por: Orange, Jordan S., et al.
Publicado: (2013)

Transient hypogammaglobulinemia and severe atopic dermatitis: Open-label treatment with immunoglobulin in a case series
por: Breslin, Moira E., et al.
Publicado: (2016)

Outcome Evaluation of a Subcutaneous Immunoglobulin Clinical Management Program
por: Zhu, Julia, et al.
Publicado: (2019)

Clinical and economic outcomes of a “high-touch” clinical management program for intravenous immunoglobulin therapy
por: Zhu, Julia, et al.
Publicado: (2017)

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2012)

Trastornos inmunológicos en lactantes y niños
por: Stiehm, E. Richard, 1933-

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
por: Hagan, John B., et al.
Publicado: (2010)

A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder
por: Rossignol, Daniel A, et al.
Publicado: (2021)

Hypohidrotic Ectodermal Dysplasia and Immunodeficiency with Coincident NEMO and EDA Mutations
por: Keller, Michael D., et al.
Publicado: (2011)

Why Do Some People Develop Serious COVID-19 Disease After Infection, While Others Only Exhibit Mild Symptoms?
por: Ballow, Mark, et al.
Publicado: (2021)

Reply to “Patient variability in severity of COVID-19 disease. Main suspect: vascular endothelium”
por: Ballow, Mark, et al.
Publicado: (2021)

Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases
por: Ballow, Mark, et al.
Publicado: (2022)

Specific Immunotherapy in a Murine Model of Grass Pollen (Phl p5b)-Induced Airway Inflammation
por: Stiehm, Matthias, et al.
Publicado: (2021)

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
por: Orange, J S, et al.
Publicado: (2012)

Adaptive and Innate Immune Responses in Autism: Rationale for Therapeutic Use of Intravenous Immunoglobulin
por: Gupta, Sudhir, et al.
Publicado: (2010)

Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin
por: Galeotti, Caroline, et al.
Publicado: (2010)

IMMUNOGLOBULINS IN NZB/BL MICE : I. SERUM IMMUNOGLOBULIN LEVELS AND IMMUNOGLOBULIN CLASS OF ERYTHROCYTE AUTOANTIBODY
por: Warner, Noel L., et al.
Publicado: (1968)

How I Manage Natural Killer Cell Deficiency
por: Orange, Jordan S.
Publicado: (2019)

Comparison of Two Different Criteria for Specific Antibody Deficiency in Patients With Chronic and Recurrent Rhinosinusitis
por: Chernikova, Diana, et al.
Publicado: (2020)

Arabinosylation of recombinant human immunoglobulin-based protein therapeutics
por: Hossler, Patrick, et al.
Publicado: (2017)

Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury
por: Thom, Vivien, et al.
Publicado: (2017)

4547 Understanding the molecular mechanism of natural killer cell deficiency to improve natural killer cell in vitro differentiation for therapeutics
por: Schmit, Megan, et al.
Publicado: (2020)

Degranulation enhances presynaptic membrane packing, which protects NK cells from perforin-mediated autolysis
por: Li, Yu, et al.
Publicado: (2021)

Pulmonary Granulomas in a Patient on MER Therapy
por: Lundy, Joel, et al.
Publicado: (1977)

Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics
por: Roberts, Graham, et al.
Publicado: (2020)

Potential therapeutic approach of intravenous immunoglobulin against COVID-19
por: Kolahchi, Zahra, et al.
Publicado: (2021)

Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases
por: Lee, Lucia, et al.
Publicado: (2021)

Gut Microbes in Immunoglobulin A Nephropathy and Their Potential Therapeutic Applications
por: Wang, Yi, et al.
Publicado: (2022)

Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin
por: Otsubo, Ryota, et al.
Publicado: (2022)

Therapeutic Uses of Rituximab and Clinical Features in Immunoglobulin G4-Related Disease: A Systematic Review
por: Patel, Utkarsh, et al.
Publicado: (2023)

Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
por: Chen, Shixue, et al.
Publicado: (2019)

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
por: Deng, Mi, et al.
Publicado: (2021)

Dual channel STED nanoscopy of lytic granules on actin filaments in natural killer cells
por: Mace, Emily M., et al.
Publicado: (2012)

Presentation of hemophagocytic lymphohistiocytosis due to a novel MUNC 13–4 mutation masked by partial therapeutic immunosuppression
por: Garrett, Jackie P-D, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hhret54f8dr85jdu69ge8fgktb